Related Experiment Videos
Hereditary and acquired antithrombin deficiency.
1Laboratory for Blood Coagulation, Linz, a.D., Austria.
Seminars in Thrombosis and Hemostasis
|August 12, 1999
Summary
Antithrombin (AT) deficiency, a condition impacting blood clotting, can be congenital or acquired. AT substitution therapy is crucial for managing thrombotic events, especially in disseminated intravascular coagulation (DIC).
Area of Science:
- Hematology
- Biochemistry
Background:
- Antithrombin (AT) is a key inhibitor of activated coagulation enzymes.
- AT deficiency can arise from congenital defects or acquired conditions like reduced production, increased loss, or consumption.
- These deficiencies increase the risk of thrombotic events.
Purpose of the Study:
- To describe the different types of antithrombin deficiency.
- To outline therapeutic and prophylactic strategies for AT deficiency.
- To highlight the importance of AT substitution in managing thrombotic tendencies and disseminated intravascular coagulation (DIC).
Main Methods:
- Review of existing literature on antithrombin deficiency.
- Analysis of clinical data regarding AT substitution therapy.
- Evaluation of treatment outcomes in patients with AT deficiency and DIC.
Main Results:
- AT deficiency presents in various forms, including reduced molecular quantity, diminished activity, or decreased heparin sensitivity.
- Acquired deficiencies stem from factors affecting AT production, loss, or consumption.
- AT substitution therapy, particularly with purified concentrates, has shown significant benefits in managing thrombotic risks and is life-saving in DIC cases.
Conclusions:
- Antithrombin deficiency is a significant risk factor for thrombosis.
- Therapeutic substitution with antithrombin concentrates is effective, especially in critical conditions like DIC.
- Prompt AT substitution can be life-saving in patients with severe coagulopathies.